



Press release

***Global Life Science Ventures* announces lead investment into Intercell AG**

Munich/Zug/London, 17 July 2003 – *Global Life Science Ventures (GLSV)* today announces that it has made a significant investment in vaccine development company Intercell AG. GLSV is the lead investor in the financing round which raised € 30 million for the international biotechnology company located in Vienna, Austria. Hans A. Küpper, the Munich-based Partner of GLSV, will join Intercell's Supervisory Board.

Founded in 1998, Intercell AG is developing novel therapeutic and preventative vaccines against infectious diseases including hepatitis C and tuberculosis, and against certain types of cancer. The development of so-called "smart vaccines" is possible owing to unique proprietary technologies that enable antigen identification and synthesis as well as the strengthening of the T-cell immune response by "immunizers" (adjuvants). The company's therapeutic hepatitis C vaccine is currently being tested in a phase II clinical trial to assess safety, efficacy and dosage. A Japanese encephalitis vaccine is being prepared to enter phase III clinical trials. In addition, a cancer vaccine and immunizer are also being evaluated in early human trials for cancer treatment in collaboration with the Ludwig Institute for Cancer Research (USA). Intercell employs about 100 people at its facility located on the Campus Vienna Biocenter.

"Classical vaccine development has progressed into a science-driven business that offers high growth potential," commented Hans A. Küpper, PhD, Partner of Global Life Science Ventures. He added: "Intercell has a strong management team which has already demonstrated the ability to rapidly advance its projects to the clinic. With its novel approach to vaccine development, the company fits well into the investment focus of the GLSV portfolio."

Alexander von Gabain, PhD, Chief Executive Officer and co-founder of Intercell AG, commented: "We are extremely pleased that Global Life Science Ventures has chosen to be lead investor in our financing round. The strengthening of our financial position and broadening of our investor base will help considerably as we advance our prophylactic and therapeutic vaccine development programs, including our later-stage clinical projects, to commercial viability."

About Global Life Science Ventures:

GLSV is a leading, independent venture capital fund focusing exclusively on the life sciences. With offices in Germany, Switzerland, and the UK, GLSV is dedicated to providing finance primarily to early-stage groups, originating from universities, scientific institutions or industry, as well as selected later stage companies, including buy-outs. The group currently advises and manages funds greater than €200 million. Up to now, GLSV has financed 20 leading biotechnology companies, four of which have completed a successful exit through IPO or trade-sale. GLSV has built a broadly diversified portfolio of companies in pharmaceuticals, diagnostics, medical devices, and biotechnology.



Global Life Science Ventures – one team – three locations – global perspective

Germany

GLSV GmbH
Von-der-Tann-Str. 3
D – 80539 München
Tel. +49 (0)89 288 151 0
Fax +49 (0)89 288 151 30

Switzerland

GLSV AG
Postplatz 1, P.O. 626
CH – 6301 Zug
Tel. +41 (0)41 727 19 40
Fax +41 (0)41 727 19 45

UK

GLSV Ltd.
1, Northumberland Avenue
London WC2N 5BW, UK
Tel. +44 (0)20 89 38 66 92
Fax +44 (0)20 89 38 77 40

www.glsv-vc.com
mailbox@glsv-vc.com

For additional information, please contact:

Rochat & Partners

Christophe Lamps
Tel. +41 22 718 37 46
Fax +41 22 786 54 58
E-mail: clamps@rochat-pr.ch